Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMNMNASDAQ:QURENASDAQ:SLSNASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMNMImmunome$8.69-1.7%$8.66$5.15▼$16.81$769.19M1.92892,421 shs1.06 million shsQUREuniQure$14.31-0.8%$14.54$3.76▼$19.18$789.86M0.081.96 million shs633,417 shsSLSSELLAS Life Sciences Group$2.17$1.73$0.77▼$2.27$216.52M2.311.74 million shs3.80 million shsSNDXSyndax Pharmaceuticals$8.73-3.0%$10.41$8.58▼$25.07$774.43M0.71.84 million shs1.75 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMNMImmunome-0.23%-6.56%-4.82%+56.29%-27.76%QUREuniQure-1.21%+2.65%-17.14%+71.58%+272.66%SLSSELLAS Life Sciences Group-0.23%-0.91%+34.78%+108.65%+79.34%SNDXSyndax Pharmaceuticals-5.89%-6.73%-23.76%-17.33%-58.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMNMImmunome2.412 of 5 stars3.52.00.00.02.62.50.0QUREuniQure2.0872 of 5 stars3.51.00.00.01.52.50.6SLSSELLAS Life Sciences Group0.121 of 5 stars0.01.00.00.00.01.70.6SNDXSyndax Pharmaceuticals3.0993 of 5 stars3.51.00.04.41.20.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMNMImmunome 3.00Buy$23.33168.51% UpsideQUREuniQure 2.91Moderate Buy$37.82164.28% UpsideSLSSELLAS Life Sciences Group 0.00N/AN/AN/ASNDXSyndax Pharmaceuticals 2.90Moderate Buy$35.80310.08% UpsideCurrent Analyst Ratings BreakdownLatest SLS, SNDX, IMNM, and QURE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/30/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.005/29/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.005/19/2025QUREuniQureCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/13/2025IMNMImmunomeWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$33.00 ➝ $21.005/12/2025QUREuniQureGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.00 ➝ $28.005/12/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.005/6/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $38.005/6/2025SNDXSyndax PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$16.00 ➝ $17.005/6/2025SNDXSyndax PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.004/21/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMNMImmunome$9.04M83.64N/AN/A$2.27 per share3.83QUREuniQure$27.12M28.90N/AN/A($0.14) per share-102.21SLSSELLAS Life Sciences Group$1M216.52N/AN/A$0.13 per share16.69SNDXSyndax Pharmaceuticals$23.68M31.72N/AN/A$3.38 per share2.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMNMImmunome-$292.96M-$3.18N/AN/AN/A-1,875.21%-71.65%-60.36%8/11/2025 (Estimated)QUREuniQure-$239.56M-$4.39N/AN/AN/A-1,077.05%-483.87%-34.28%8/7/2025 (Estimated)SLSSELLAS Life Sciences Group-$30.88M-$0.38N/AN/AN/AN/A-193.67%-113.02%8/12/2025 (Estimated)SNDXSyndax Pharmaceuticals-$318.76M-$3.86N/AN/AN/A-757.53%-101.60%-58.41%8/7/2025 (Estimated)Latest SLS, SNDX, IMNM, and QURE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SLSSELLAS Life Sciences Group-$0.1067-$0.07+$0.0367-$0.07N/AN/A5/12/2025Q1 2025IMNMImmunome-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million5/9/2025Q1 2025QUREuniQure-$1.07-$0.82+$0.25-$0.82$5.93 million$1.57 million5/5/2025Q1 2025SNDXSyndax Pharmaceuticals-$1.04-$0.98+$0.06-$0.98$15.88 million$20.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMNMImmunomeN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMNMImmunomeN/A10.4910.49QUREuniQure1.5311.9911.99SLSSELLAS Life Sciences GroupN/A4.644.64SNDXSyndax Pharmaceuticals1.535.805.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMNMImmunome44.58%QUREuniQure78.83%SLSSELLAS Life Sciences Group17.38%SNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipIMNMImmunome8.60%QUREuniQure4.79%SLSSELLAS Life Sciences Group1.20%SNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMNMImmunome4087.01 million79.53 millionOptionableQUREuniQure50054.78 million52.15 millionOptionableSLSSELLAS Life Sciences Group1099.78 million98.58 millionNot OptionableSNDXSyndax Pharmaceuticals11086.05 million82.52 millionOptionableSLS, SNDX, IMNM, and QURE HeadlinesRecent News About These CompaniesSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 (c) (4) - MorningstarJuly 3, 2025 | morningstar.comMSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)July 2, 2025 | globenewswire.comSyndax Pharmaceuticals, Inc. (SNDX) - Yahoo FinanceJune 27, 2025 | finance.yahoo.comSNDX Syndax Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comSyndax Pharmaceuticals Inc News (SNDX) - Investing.comJune 26, 2025 | investing.comSyndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia - MorningstarJune 25, 2025 | morningstar.comMSyndax Gets Priority Review for Leukemia Drug ApplicationJune 24, 2025 | marketwatch.comSyndax stock rises after FDA grants Priority Review for cancer drug expansionJune 24, 2025 | investing.comSyndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML TrialJune 24, 2025 | msn.comSyndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid LeukemiaJune 24, 2025 | globenewswire.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by BrokeragesJune 21, 2025 | marketbeat.comSyndax reports publication of revumenib data from BEAT AML trialJune 13, 2025 | msn.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Assenagon Asset Management S.A.June 13, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.7% - Time to Sell?June 12, 2025 | marketbeat.comSyndax Pharma releases new data from its AUGMENT-101 trial of RevuforjJune 12, 2025 | thepharmaletter.comTSyndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025June 12, 2025 | globenewswire.comSyndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025June 12, 2025 | globenewswire.comSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)June 5, 2025 | globenewswire.comKura Posts New Data, Secures NDA Acceptance in Acute Myeloid Leukemia Race With SyndaxJune 3, 2025 | biospace.comBSyndax Announces Participation in June Investor ConferencesMay 29, 2025 | globenewswire.comSyndax Pharmaceuticals Inc.May 21, 2025 | wsj.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLS, SNDX, IMNM, and QURE Company DescriptionsImmunome NASDAQ:IMNM$8.69 -0.15 (-1.70%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$8.84 +0.15 (+1.71%) As of 07/7/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.uniQure NASDAQ:QURE$14.31 -0.11 (-0.76%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$14.40 +0.09 (+0.66%) As of 07/7/2025 05:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.SELLAS Life Sciences Group NASDAQ:SLS$2.17 0.00 (0.00%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$2.17 +0.00 (+0.23%) As of 07/7/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Syndax Pharmaceuticals NASDAQ:SNDX$8.73 -0.27 (-3.00%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$8.76 +0.03 (+0.29%) As of 07/7/2025 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
